Literature DB >> 29278427

Gastric pyloric gland adenoma: a multicentre clinicopathological study of 67 cases.

Won-Tak Choi1, Ian Brown2, Tetsuo Ushiku3, Masato Yozu4, Namrata Setia5, Amitabh Srivastava6, Melanie Johncilla6, Rish K Pai7, Ryan M Gill1, Masashi Fukayama3, Joseph Misdraji4, Gregory Y Lauwers8.   

Abstract

AIMS: There is limited information regarding the clinicopathological and immunohistochemical characteristics of gastric pyloric gland adenomas (PGAs). METHODS AND
RESULTS: Sixty-seven cases of gastric PGA from 57 patients were analysed. PGAs occurred with similar frequency in men and women (47.4 and 52.6%, respectively), with a mean age of 66 years. Most presented in the gastric body/fundus (67.2%). Fifteen cases (22.4%) developed against a background of autoimmune gastritis (AIG), whereas normal mucosa was seen in 35.8%. Only 16.4% (11 cases) developed in patients with a genetic predisposition, most commonly familial adenomatous polyposis. Low-grade lesions had a mean size of 1.5 cm, while PGAs with high-grade dysplasia (HGD) or adenocarcinoma had a mean size of 3.5 cm (P < 0.001) and more commonly showed tubulovillous architecture (50.0 versus 25.6% in low-grade dysplasia; P = 0.040). Most PGAs (61.2%) co-expressed mucin (MUC)5AC and MUC6 (mixed type), which was associated significantly with HGD or adenocarcinoma (P = 0.013). AIG was also associated with HGD (P = 0.027), but genetic predisposition did not correlate with the grade of dysplasia (P = 0.793). The recurrence rate of PGA was similar for high- (11.8%) and low-grade lesions (7.4%) (P = 0.624).
CONCLUSIONS: The risk of HGD increases with the size of PGA, tubulovillous architecture and the presence of AIG as well as mixed immunophenotype. As the overall local recurrence rate is less than 10%, PGAs may be treated conservatively, but they should be excised completely if possible, particularly if they are large or show high-grade features.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  autoimmune gastritis; dysplasia; pyloric gland adenoma

Mesh:

Substances:

Year:  2018        PMID: 29278427     DOI: 10.1111/his.13460

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  6 in total

Review 1.  Self-Renewal and Cancers of the Gastric Epithelium: An Update and the Role of the Lectin TFF1 as an Antral Tumor Suppressor.

Authors:  Werner Hoffmann
Journal:  Int J Mol Sci       Date:  2022-05-11       Impact factor: 6.208

2.  Case Report: Two Is Not (Always) Better Than One: Pyloric Gland Adenoma of the Gastric Cardia and Concurrent Neuroendocrine Cell Dysplasia Arising From Autoimmune Gastritis.

Authors:  Camilla Guerini; Marco Vincenzo Lenti; Chiara Rossi; Giovanni Arpa; Andrea Peri; Anna Gallotti; Antonio Di Sabatino; Alessandro Vanoli
Journal:  Front Med (Lausanne)       Date:  2022-05-19

3.  Gastric pyloric gland adenoma resembling a submucosal tumor: A case report.

Authors:  Cong-Cong Min; Jun Wu; Feng Hou; Tao Mao; Xiao-Yu Li; Xue-Li Ding; Hua Liu
Journal:  World J Clin Cases       Date:  2020-06-06       Impact factor: 1.337

4.  Pyloric Gland Adenoma of the Esophagus Treated by Endoscopic Submucosal Dissection: A Case Report.

Authors:  Kwangbeom Park; Do Hoon Kim; Sung Duck Lee; Hyun Lee; Hwoon-Yong Jung
Journal:  Gut Liver       Date:  2022-05-15       Impact factor: 4.519

Review 5.  Pyloric gland adenoma with low-grade intraepithelial neoplasia: A case report and literature review.

Authors:  Hai-Long Li; Yan Wang; Yu-Bo Ren; Xue-Song Yang; Li Wang; Lei Zhang; Xiang-Chun Lin
Journal:  Medicine (Baltimore)       Date:  2021-06-25       Impact factor: 1.889

6.  Genetic alteration of colorectal adenoma-carcinoma sequence among gastric adenocarcinoma and dysplastic lesions in a patient with attenuated familial adenomatous polyposis.

Authors:  Hiroki Tanabe; Kentaro Moriichi; Keitaro Takahashi; Yusuke Ono; Yu Kobayashi; Yuki Murakami; Takuya Iwama; Takehito Kunogi; Takahiro Sasaki; Katsuyoshi Ando; Nobuhiro Ueno; Shin Kashima; Hidehiro Takei; Yusuke Mizukami; Mikihiro Fujiya; Toshikatsu Okumura
Journal:  Mol Genet Genomic Med       Date:  2020-06-16       Impact factor: 2.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.